BioSpace News Archive

Momentis Surgical™ Ltd, a medical device company dedicated to transforming surgery with its proprietary surgical robotic technology, today announced that Lee Health has acquired the Anovo™ Surgical System, the first and only FDA-authorized surgical robot with features designed to mimic human arms and provide human level dexterity.

A recent survey of the celiac disease community by Beyond Celiac, the leading catalyst for a celiac disease cure, reveals the ongoing challenges those with the disease are facing on National Celiac Disease Awareness Day, Sept. 13, and the overwhelming desire for new treatments and a cure.

Pear Therapeutics, Inc. today announced the company will participate in the LifeSci Partners HealthTech Symposium on September 20, 2022.

WCG, the world’s leading provider of solutions that measurably improve the quality and efficiency of clinical research, today announced the expansion of its Phase I review services, providing purpose-built operations for Phase I investigators.

ONWARD Medical N.V. announced that the Up-LIFT pivotal study evaluating ARC-EX Therapy achieved its primary effectiveness endpoint of improvement in upper extremity strength and function. ARC-EX Therapy is a proprietary non-invasive spinal cord stimulation technology designed to restore movement and other functions in people with movement disabilities.

The World Health Summit and the World Health Organization as co-organizer jointly invite to the world’s leading global health conference.

One Biosciences announced that it initiated the LARYCARE prospective clinical study for single-cell profiling of larynx and hypopharynx carcinoma.

Ventris Medical, a privately held orthobiologics and tissue regeneration company, announced that the United States Food and Drug Administration has granted 510 clearance for Synthetic Bone Graft Putty.

Alnylam Pharmaceuticals, Inc. announced the pricing of its previously announced private offering of $900 million aggregate principal amount of 1.00% convertible senior notes due 2027 to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

Akeso, Inc. published encouraging preclinical results in poster featuring its Fc-mutant anti-TIGIT antibody fused with TGF-βRII protein at the European Society for Medical Oncology Congress 2022.